ClinicalTrials.gg
Drug

Raltegravir clinical trials

Also written Isentress and MK-0518.

studies test it
176
open now
2
in phase 3
35
first study started
2005

How each study uses raltegravir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the raltegravir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
12 Oct 2007 · ISENTRESS HD · NDA 022145 (FDA, Drugs@FDA)
European Union
19 Dec 2007 · Isentress · EMEA/H/C/000860 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Raltegravir
110
RAL
12
raltegravir potassium
3
Raltegravir (MK-0518)
3
Raltegravir chewable tablet
2

Brand

Isentress
61

Development codes

MK-0518
13

In one entry with another drug

Given together, or one or the other

Kaletra + Isentress
2
raltegravir plus truvada
2

Studies by the year they started

176 studies that test it; most in 2008 (36)

Studies that test raltegravir, by start year
YearStudies
20052
20063
200713
200836
200925
201028
201115
201212
201311
201413
20158
20173
20184
20191
20201
20211

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
34
Phase 2
29
Phase 3
35
Phase 4
58
No phase
25

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 28 · Other 148

Merck Sharp & Dohme LLC (16) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · ANRS, Emerging Infectious Diseases (6) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (5) · Radboud University Medical Center (5) · University of California, San Francisco (5) · Kirby Institute (4) · Germans Trias i Pujol Hospital (4)

Often tested with

Tested in the same studies.

Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (13) · Lamivudine (12) · Tenofovir (11) · Ritonavir (11) · Emtricitabine (8) · Maraviroc (8) · Darunavir (7) · Atazanavir (7)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses raltegravir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 176

See all 176 studies that test raltegravir →

Given beside what is tested · 13 — raltegravir is usual care or a partner of the new treatment
As the comparator · 6 — what is tested is compared with raltegravir

Codes

What other systems call raltegravir · ClinicalTrials.gg INT006558

  • MeSH (NLM) D000068898Raltegravir PotassiumConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 22VKV8053URALTEGRAVIRConfirmed FDA, NLM, Wikidata
  • RxNorm 719872Confirmed FDA, Wikidata
  • Wikidata Q421552raltegravirConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C72837RaltegravirOne source FDA
  • DrugBank DB06817One source Wikidata

Also registered as raltegravir potassium (UNII 43Y000U234 · RxNorm 1235585).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.